Search PubMed⌕ Search

Biomedical subjects

J E Castro

Publications and source records attributed to J E Castro.

At least 109 records · Page 6Linked to original sources
PubMed1969

Significance of signs and symptoms in benign prostatic hypertrophy.

Measurements of intravesical pressure, urinary flow rate, retrograde cystographic residual urine, reflux of contrast medium into the prostatic ducts, and radiological prostate size were made in 45 men with benign prostatic hypertrophy. These factors were all found to be good clinical indices of the degree of urethral resistance to micturition; on the other hand, there was no relation between the latter and the severity of symptoms.

Humans↗
PubMedDate not supplied

Mechanism of action of C. parvum on a solid, subcutaneous mouse tumour.

The effects of i.v. C. parvum on the growth of a.s.c. inoculum of the Lewis lung carcinoma were studied in normal C57 B1 mice, and in those in which separate components of the immune response were impaired. C. parvum given either at the same time as tumour inoculation or when the carcinoma was 1 cm in diameter, and fully vascularised, reduced tumour growth. Macrophages were impaired by silica (Si), cortisone acetate (CA) or trypan blue (TB), and T cells by thymectomy and sublethal irradiation (TXR) or antilymphocyte serum (ALS). TB did not affect tumour size, whereas Si, CA, TXR, or ALS (initiated before tumour inoculation) reduced it. When C. parvum was given in combination with TB, or ALS (initiated after tumour inoculation), its antitumour effects were unchanged. C. parvum given after ALS (before tumour), TXR, Si, or CA had no further effect on tumour growth. We have shown that C. parvum inhibits the growth of inoculated Lewis tumour. However, it has not been possible to clearly define in vivo the immunological mechanisms involved.

Animals↗
PubMedDate not supplied

Clinical studies with Corynebacterium parvum.

In a pilot study twelve patients with malignant disease were treated with Corynebacterium parvum. The clinical results were encouraging. A prospective randomised controlled clinical trial of C. parvum therapy in the treatment of patients with carcinoma of the bronchus began in August 1976. 22 pateints have been admitted to the trial and 11 treated with C. parvum. Clinical progress is reported. Radiological, haematological, biochemical and immunological measurements have been made and these results are presented with emphasis on the immunological data. Marked elevation of C. parvum antibody titre occurs. Lymphocyte reactivity, assessed by responses to phytohaemagglutinin and poke-weed mitogen and by the formation of T and B-cell rosettes, was significantly depressed in all patients compared to healthy volunteers, but in patients receiving C. parvum there is a relative increase in B-lymphocyte activity. Mild platelet depression occurs. No alteration to complement activity has been detected.

Adult↗